After rebuffing Biogen, Sage pairs off with Supernus
Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
J&J says two drugs are better than one in pretreated myeloma
Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
Former CEO wins bidding war for 23andMe, beating Regeneron
23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.
DMD gene therapy Elevidys linked to new liver failure case
Another death from liver failure has been seen with Roche and Sarepta's Duchenne muscular dystrophy therapy Elevidys, prompting a pause on treatment.
Streeting pledges clinical trial signups in the NHS App
Millions of people in the UK will be given the opportunity to take part in clinical trials via the NHS App.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
EVERSANA expands commercialisation portfolio with OS Therapi...
EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic partnerships to support the US commercialisation of innovative therapies from O
The Pharmaceutical Marketing Society and the Chartered Insti...
The PM Society is delighted to announce a new partnership with the CIM to build capability and excellence in marketing in the pharmaceutical industry.
15th World Clinical Biomarkers & Companion Diagnostics Summi...
The biomarkers and diagnostics field continues to boom, driven by advancements in genomic profiling, omics, and AI technologies.
5th iPSC Drug Development Summit
Advance iPSC therapies from bench to bedside with 30+ industry experts at this year’s summit.
Axtria Ignite 2025: Leading in an Agentic Era
Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This